-
Bestatin and Angiotensin III in Rat Brain
2026-09-17
The reference study used aminopeptidase inhibitors, iontophoretic peptide delivery, and neuronal recording to test whether angiotensin II must be converted to angiotensin III before activating rat brain neurons. Its contrasting effects of bestatin and amastatin support a sequential processing model while also illustrating the limits of inferring enzyme pathways from pharmacology alone.
-
RPS27L/RPS27 Neddylation and Cancer Cell Survival
2026-09-17
The reference study identifies RPS27L and RPS27 as previously unrecognized neddylation substrates regulated by MDM2 and NEDP1. Its findings connect NAE inhibition to reduced ribosomal-protein stability and apoptosis sensitivity, adding a substrate-level explanation to the broader effects of neddylation pathway inhibition in cancer cells.
-
RPS6: Translational Readout of PDAC Growth
2026-09-16
RPS6 sits at the intersection of membrane signaling, ribosome biogenesis, and proliferative biomass production. This thought-leadership article interprets recent LRRC8A–Caveolin-1 findings in pancreatic ductal adenocarcinoma and presents the Anti-RPS6 (7B10) Mouse Monoclonal Antibody as a practical tool for building orthogonal, translationally relevant assays.
-
Exosomal HMGB1 in Lupus Nephritis Endothelial Injury
2026-09-15
The reference study identifies podocyte-derived exosomal HMGB1 as a mechanistic signal that promotes glomerular endothelial cell injury in lupus nephritis through TRIM27 regulation. Its combination of patient material, lupus-like mouse models, exosome perturbation, and genetic validation provides a framework for dissecting podocyte–endothelial communication and evaluating GW 4869 as an experimental exosome-release inhibitor.
-
(R)-MG132 for Proteasome Mechanism Controls
2026-09-15
Use (R)-MG132 as a stereochemical negative control to distinguish genuine proteasome-dependent phenotypes from solvent, scaffold, and cellular stress artifacts. Its value is greatest in paired biochemical and cell-based workflows that test whether protein stability or cancer-metabolism changes depend on proteasome inhibition.
-
CX-5461: A Precision Workflow for Pol I Stress
2026-09-14
CX-5461 is an RNA polymerase I inhibitor whose effects extend from rRNA suppression to DNA damage, mitotic catastrophe, autophagy, and senescence. This guide translates the latest cervical cancer findings into a decision-oriented workflow for mechanistic cancer research and cross-model validation.
-
Salvianolic acid B: Reading Fibrotic Matrix State
2026-09-14
Salvianolic acid B, also known as Dan Shen Suan B, offers a matrix-centered framework for pulmonary fibrosis research. This article explains how to distinguish collagen abundance from LH2-dependent collagen quality and design more causally informative antifibrotic assays.
-
Zoledronic Acid: Cancer and Bone Research
2026-09-13
Zoledronic Acid is a nitrogen-containing bisphosphonate used in cancer and bone biology research. Its established antiresorptive mechanism involves farnesyl pyrophosphate synthase inhibition, while product-reported in vitro studies describe concentration-dependent antiproliferative and pro-apoptotic effects.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-09-12
This bioRxiv preprint shows that selected kinase inhibitors can both suppress p38α catalytic activity and accelerate removal of its activation-loop phosphate by WIP1. Structural and biochemical data link this dual action to a flipped activation-loop conformation that exposes the phospho-threonine, suggesting a strategy for designing more selective kinase inhibitors.
-
Salvianolic acid B: Reliable Cell Assays
2026-09-12
Learn how Salvianolic acid B (SKU N1806) can improve the interpretability of viability, proliferation, and pulmonary fibrosis assays through controlled formulation, orthogonal readouts, and mechanistic controls. This scenario-based guide connects assay troubleshooting with evidence on LH2 expression, collagen remodeling, and product selection.
-
Salvianolic acid B: A Matrix-First Research Guide
2026-09-11
Salvianolic acid B, also known as Dan Shen Suan B, is emerging as a research tool for connecting LH2 regulation with collagen remodeling in pulmonary fibrosis. This guide translates the latest mechanistic evidence into assay-design and compound-handling decisions.
-
Fluo-4 AM Workflows for Calcium Signaling
2026-09-11
Build sensitive, real-time calcium signaling assays with Fluo-4 AM, from loading optimization to pharmacological response profiling. A ferroelectric artificial photoreceptor study provides a useful cross-disciplinary framework for choosing optical and electrophysiological readouts without overstating what the indicator can prove.
-
Salvianolic Acid B, LH2, and Pulmonary Fibrosis
2026-09-10
The reference study identifies Salvianolic acid B as an antifibrotic compound that suppresses LH2/PLOD2-associated collagen cross-linking in pulmonary fibrosis. Its findings connect reduced LH2 expression with lower collagen deposition, inhibition of EMT and FMT, and modulation of Wnt/β-catenin signaling, providing a mechanistic framework for matrix-focused research.
-
Propranolol and Primidone Mechanisms in Essential Tremor
2026-09-10
A 2024 prospective observational study used transcranial magnetic stimulation and accelerometry to distinguish how primidone and propranolol alter motor-cortical physiology in essential tremor. The findings associate primidone with broader GABAergic and corticospinal changes, whereas propranolol shows a narrower profile involving reduced corticospinal excitability and increased short afferent inhibition.
-
Salvianolic acid B: LH2 Workflow for Fibrosis
2026-09-09
Build a practical pulmonary fibrosis assay around Salvianolic acid B, from solution preparation and dose design to LH2, collagen, EMT, and matrix-remodeling readouts. The workflow distinguishes reduced collagen abundance from altered collagen cross-linking, helping position Dan Shen Suan B as a mechanistically useful antifibrotic research compound rather than a nonspecific viability hit.